These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31852833)

  • 1. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.
    Pairawan S; Hess KR; Janku F; Sanchez NS; Mills Shaw KR; Eng C; Damodaran S; Javle M; Kaseb AO; Hong DS; Subbiah V; Fu S; Fogelman DR; Raymond VM; Lanman RB; Meric-Bernstam F
    Clin Cancer Res; 2020 Apr; 26(8):1924-1931. PubMed ID: 31852833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.
    Janku F; Zhang S; Waters J; Liu L; Huang HJ; Subbiah V; Hong DS; Karp DD; Fu S; Cai X; Ramzanali NM; Madwani K; Cabrilo G; Andrews DL; Zhao Y; Javle M; Kopetz ES; Luthra R; Kim HJ; Gnerre S; Satya RV; Chuang HY; Kruglyak KM; Toung J; Zhao C; Shen R; Heymach JV; Meric-Bernstam F; Mills GB; Fan JB; Salathia NS
    Clin Cancer Res; 2017 Sep; 23(18):5648-5656. PubMed ID: 28536309
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
    Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
    Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
    Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
    Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
    Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
    Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
    Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma.
    Sumiyoshi T; Yamasaki T; Takeda M; Mizuno K; Utsunomiya N; Sakamoto H; Nakamura E; Ogawa O; Akamatsu S
    Cancer Sci; 2021 Aug; 112(8):3363-3374. PubMed ID: 34009695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
    Chapin WJ; Till JE; Hwang WT; Eads JR; Karasic TB; O'Dwyer PJ; Schneider CJ; Teitelbaum UR; Romeo J; Black TA; Christensen TE; Redlinger Tabery C; Anderson A; Slade M; LaRiviere M; Yee SS; Reiss KA; O'Hara MH; Carpenter EL
    JCO Precis Oncol; 2022 Jul; 6():e2200060. PubMed ID: 35939771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
    Bagley SJ; Nabavizadeh SA; Mays JJ; Till JE; Ware JB; Levy S; Sarchiapone W; Hussain J; Prior T; Guiry S; Christensen T; Yee SS; Nasrallah MP; Morrissette JJD; Binder ZA; O'Rourke DM; Cucchiara AJ; Brem S; Desai AS; Carpenter EL
    Clin Cancer Res; 2020 Jan; 26(2):397-407. PubMed ID: 31666247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.
    Lee DW; Lim Y; Kim HP; Kim SY; Roh H; Kang JK; Lee KH; Kim MJ; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Cancer Res Treat; 2023 Jul; 55(3):927-938. PubMed ID: 36915247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
    Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
    Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
    Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
    Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.